Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KLF3 antisense RNA 1 (KLF3-AS1, FLJ13197) is a long non-coding RNA (lncRNA) located on chromosome 4. It functions primarily by binding microRNAs (such as miR-185-5p, miR-223, miR-206, miR-138-5p, and miR-383), thereby regulating downstream gene expression, including the activation of KLF3 and other targets. KLF3-AS1 plays a tumor-suppressive role in several cancers (notably esophageal squamous cell carcinoma and gastric cancer), where its upregulation is associated with reduced tumor growth, invasion, and chemoresistance. It also promotes cartilage repair and chondrocyte survival in osteoarthritis, enhances angiogenesis and tissue repair in wound healing, and protects cardiomyocytes from ischemic injury. The molecule has emerged as a multifunctional regulator with therapeutic potential across a range of pathological states
Acts as a competing endogenous RNA (ceRNA), "sponging" specific miRNAs (e.g., miR-185-5p, miR-223, miR-206, miR-138-5p, miR-383) to regulate gene expression in target cells and tissues
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KLF3 antisense RNA 1 (KLF3-AS1).